|
|
发表于 2013-4-6 12:03:30
|
显示全部楼层
来自： 美国
Lucanix vaccine is based on another 'cancer cell cloak' molecule, TGF-beta. It is at least 3-4 years ahead of this CD47 discovery in terms of human trials, and it has been working well for many patients. Apparently some people have been getting it under 'CU' clause - compassionate use per FDA rule.
However, world-wide phase III clinical trial of Lucanix vaccine for lung cancer suffered setback early this year. Rumor has it that in some countries perhaps east Europe, or 仿版, for profit purpose, Doctors abused their positions and recruited many patients into the trial that did not meet trial participation criteria, therefore data obtained in these sites caused problem for the overall trial and as a result the whole phase 3 trial is now stopped. So far it has not yet restarted.
Lucanix was the most promising immunotherapy I know of for lung cancer. For some patients this was their last hope, after already trying everything else. Cuba now sells a vaccine called Cimavax that is based on EGF - I guess in theory it shall work on patients whose cancer is driven by the EGF/EGFR signaling pathway. In comparison, I suppose TGF-beta or perhaps CD47, are more universal cancer-recognition molecules, and success rate should be higher once they make into the market.
Don't raise your hopes high for CD47, as it is far far away from meaningful human application. Believe it or not, cancers in mouse are a lot easier to cure, especially implanted (or "xenografted") cancer in mouse.
To Mr/Ms 4166, I am Chinese living in the US. |
|
IP卡
狗仔卡
显身卡
